Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
White Widow is a prominent hybrid cannabis strain, characterized by its Sativa-dominant profile and high resin production. Originally bred in the Netherlands by Green House Seeds in the early 1990s, it is a genetic cross between a Brazilian Sativa landrace and a resin-heavy South Indian Indica hybrid. The strain's pharmacological profile is defined by a high concentration of delta-9-tetrahydrocannabinol (THC) and a diverse terpene profile, including myrcene, caryophyllene, and limonene. Its primary mechanism of action involves the partial agonism of the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2) within the endocannabinoid system. CB1 activation in the central nervous system mediates its psychoactive and analgesic effects, while CB2 activation contributes to its anti-inflammatory properties. White Widow is frequently utilized in medical cannabis programs for the management of chronic pain, anxiety, stress, and insomnia, offering a balance of cerebral stimulation and physical relaxation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on White Widow.